About BeiGene
BeiGene news and updates
BeiGene Ltd. is developing anti-cancer therapy ociperlimab on Jan 1st 22'.
Earlier in January, BeiGene signed a $1 billion option, collaboration, and license agreement with the renowned Swiss-based multinational pharmaceutical company Novartis International AG to develop its anti-cancer therapy ociperlimab.
Jan 1, 2022 | asiamarkets.comBeiGene Ltd. has issues with securities fraud or other unlawful business practices
The investigation concerns whether Beigene and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | prnewswire.comHuang leaves BeiGene Ltd. as Chief Medical Officer, Hematology
Dr. Huang joins Prelude from BeiGene Ltd., where she served as Chief Medical Officer, Hematology.
Jan 1, 2022 | preludetx.comBeiGene Ltd. launched BRUKINSA on Apr 8th 21'.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official launch of BRUKINSA ® (zanubrutinib) in Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
Jan 1, 2021 | businesswire.comBeiGene Ltd. is developing zanidatamab and ZW49 across various HER2-expressing malignancies and treatment options
Furthermore, Zymeworks and BeiGene are partnering on joint worldwide development for specific indications to develop zanidatamab and ZW49 across various HER2-expressing malignancies and treatment options.
Jan 1, 2021 | clinicaltrialsarena.comBeiGene Ltd. launches China approval for Blincyto
BeiGene ( BGNE ) (HKEX: 06160) (SSE: 688235) announced China approval for Blincyto® (blinatumomab) to treat pediatric patients with leukemia (see story ).
Jan 1, 2022 | seekingalpha.comBeiGene Ltd. expands offices to Basel, Switzerland
BeiGene announce the opening of a new regional office in Basel, Switzerland, which will service as a hub for the company’s operations in the region.
Jan 1, 2022 | pharmiweb.comBeiGene Ltd. is developing mRNA therapeutics
Beijing-headquartered BeiGene has formed a global strategic collaboration with InnoRNA to develop mRNA therapeutics.
Jan 1, 2022 | pda.orgBeiGene Ltd. hires Lee
View the full release here: https://www.businesswire.com/news/home/20220713005323/en/ Mr. Lee joins BeiGene from Sanofi and will bring his significant expertise leading legal functions in the biopharma industry to overseeing legal, compliance, intellectual property and related matters.
Jan 1, 2022 | beigene.comBeiGene Ltd. launched Clinical Trial Diversity Initiative on Aug 12th 21'.
For its part, BeiGene last year launched a Clinical Trial Diversity Initiative to support training for clinicians and staff in underserved communities, patient education, and advocacy efforts.
Jan 1, 2022 | forbes.comBiotechnology partners with BeiGene Ltd.
Biotechnology is delighted to partner with BeiGene, a company that strives for innovation and excellence, and is committed to developing best-in-class or first-in-class anti-cancer therapies for patients across the globe.
Jan 1, 2022 | biotechnology.reportBeiGene Ltd. partners with Ontada®
“ BeiGene is excited to work with Ontada to advance its shared vision of improving patient access, affordability, and value for community oncology stakeholders and key partners working at the intersection of clinical practice and real-world evidence.
Jan 1, 2022 | biotechnology.reportBeiGene Ltd. launched 11th regulatory submission for PD-1 Inhibitor Tislelizumab in China on Jul 25th 22'.
BeiGene recently announced acceptance of 11th regulatory submission for PD-1 Inhibitor Tislelizumab in China.
Aug 25, 2022 | benzinga.comImmune-Onc Therapeutics, Inc. partners with BeiGene Ltd.
“Immune-Onc Therapeutics, Inc. is delighted to partner with BeiGene.
Oct 9, 2022 | immune-onc.comPharmaceutical Tech partners with BeiGene Ltd.
“Pharmaceutical Tech is delighted to partner with BeiGene.
Oct 10, 2022 | pharmaceutical-tech.comBeiGene Ltd. partnered with InnoRNA on Jul 6th 22'.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics.
Jul 6, 2022 | businesswire.comBeiGene Ltd. hired Chan Lee as general counsel on Jul 18th 22'.
Chan Lee will take over as Beijing-based BeiGene’s top lawyer on July 18.
Jul 18, 2022 | law.comBeiGene Ltd. went public on Jan 1st 19'.
BeiGene has unveiled the pricing of its new IPO on China’s STAR market.
Aug 27, 2022 | fiercepharma.comTPMG partners with BeiGene Ltd.
TPMG is pleased to partner with BeiGene to raise awareness about the mental health challenges faced by people living with cancer.”
Dec 8, 2022 | tpmg.proBeiGene Ltd. partnered with Cancer Support Community on Dec 14th 22'.
Revealed at this month’s American Society of Hematology annual meeting in New Orleans, BeiGene, in collaboration with the Cancer Support Community, published its new national survey findings from “Cancer and Mental Health: The Science and Art of Whole Patient Health.”
Dec 14, 2022 | fiercepharma.com